Filing Details

Accession Number:
0000950170-24-025192
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-04 19:40:38
Reporting Period:
2024-02-29
Accepted Time:
2024-03-04 19:40:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1503802 Karyopharm Therapeutics Inc. KPTI Pharmaceutical Preparations (2834) 263931704
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1942597 Stuart Poulton C/O Karyopharm Therapeutics Inc.
85 Wells Avenue
Newton MA 02459
Evp, Chief Development Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Disposition 2024-02-29 16,311 $1.17 335,666 No 4 S Direct
Common Disposition 2024-03-01 6,155 $1.20 329,511 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
  2. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.